MBOT - Why Microbot Medical Stock Is Up | Benzinga
Microbot Medical Inc. (NASDAQ:MBOT) shares are trading higher Monday after the company announced that it has received FDA approval to proceed with its human clinical trial as part of its Investigational Device Exemption (IDE) application for its LIBERTY Endovascular Robotic Surgical System.
The Details:
Microbot said the study will be conducted in the U.S., and it has already signed a clinical trial service agreement with a leading academic medical center. In parallel to commencing the pivotal human clinical trial, the company is completing its biocompatibility tests as required by its IDE application.
"The recent authorization by the FDA to commence our pivotal clinical study, following submission of the results of our extensive pre-clinical studies and tests, reinforces our confidence in our innovative technology,” commented Harel Gadot, CEO of Microbot Medical.
“It is also a testament to our commitment to meet meaningful milestones as we ...